The Central Drugs Standard Control Organisation (CDSCO) has recently given approval to Cipla Limited to conduct a Phase IV clinical trial for its fixed-dose combination inhalation therapy. This innovative therapy consists of Glycopyrronium (as Glycopyrrolate IP) 12.5 mcg + Formoterol Fumarate Dihydrate IP 6 mcg Inhaler, aimed at providing maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Formoterol acts as a long-acting bronchodilator, while Glycopyrrolate serves as an anticholinergic, both working together to improve respiratory function. The decision to proceed with the Phase IV trial was made during the SEC Pulmonary meeting, emphasizing the importance of further evaluating the effectiveness and safety of this treatment option. Stay tuned for more updates on this groundbreaking development in the field of biotechnology.
Read more from medicaldialogues.in